Andrea Necchi: The Financial Burden of Localized and Metastatic Bladder Cancer
Andrea Necchi, Associate Editor of the Journal of Clinical Oncology, shared an article led by Pietro Scilipoti on LinkedIn about Localized and Metastatic Bladder Cancer.
The Financial Burden of Localized and Metastatic Bladder Cancer
Authors: Pietro Scilipoti, Marco Moschini, Roger Li, Seth P. Lerner, Peter C. Black, Andrea Necchi, Morgan Rouprêt, Shahrokh F. Shariat, Shilpa Gupta, Alicia K. Morgans, Sarah P. Psutka, Ashish M. Kamat
This review aims to systematically evaluate the economic burden of BCa from both healthcare and patient perspectives.
Treating non–muscle-invasive BCa (NMIBC) is particularly expensive due to ongoing surveillance and treatment, with costs for high-risk cases exceeding $200,000 over five years. Muscle-invasive BCa also generates significant expenses, with procedures like radical cystectomy (RC) and chemotherapy averaging $30,000–$40,000.
The financial burden is even greater in metastatic BCa, where systemic therapies range from $40,000 to over $100,000 per treatment cycle, further compounded by combination therapies, side effects, and supportive care needs. Financial toxicity, which is especially common among younger patients, minorities, and those with less education, highlights the economic strain of treatment.
While advancements in care improve survival and outcomes, they also increase costs, underscoring the importance of cost-effectiveness assessments and targeted efforts to reduce financial hardship and improve quality of life for patients.
Further Reading:
Immunotherapy for Bladder Cancer: Types, Success Rate, Side Effects & More
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023